XNCR logo
XNCR
Xencor

IBD Biologics And TL1A Programs Will Forge New Paths

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
06 Jul 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$28.20
73.4% undervalued intrinsic discount
24 Jul
US$7.49
Loading
1Y
-52.3%
7D
-14.2%

Author's Valuation

US$28.2

73.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value